Case Reports in Hematology / 2018 / Article / Tab 1

Case Report

An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature

Table 1

Concomitant multiple myeloma and chronic myeloid leukemia cases.

PtAge/SexYearFirst diseaseDiagnosis interval (month)Type of M-proteinTherapy for MMTherapy for CMLConfirmation method of Ph+Type of PhReference

177M1972MM33BJPNo treatmentNo treatmentChrMacSween and Langley [3]
265/F1974CML113IgG-κNo treatmentBusulfanChrDerghazarian and Whittemore [4]
358/M1982MM and CMLSimultaneousIgG-κMP, RTHU, Busulfan,ChrBoots and Pegrum [5]
471/M1993MM24IgG-κMP, RTHUChrKlenn et al. [6]
572/F1998MM and CMLSimultaneousIgG-κVPIFN-αChr, PCR, FISHP210Tanaka et al. [7]
670/M1999MM33IgG-κNot reportedNot reportedChrNitta et al. [8]
781/M2001MM and CMLSimultaneousIgA-κMPNo treatmentChr, PCRAlvarez-Larrán et al. [9]
866/M2003MM and CMLSimultaneousIgG-κMPINF-α, HU, BusulfanChr, PCR, FISHP210Schwarzmeier et al. [10]
947/M2003MM33BJPLOAD-INNot reportedChrNakagawa [11]
1068/M2005CML20IgG-λMPIFN-α, imatinibChr, PCRP210Garipidou et al. [12]
1185/F2005MM and CMLSimultaneousIgG-λNot reportedNot reportedChr, PCRP210Wakayama et al. [13]
1276/M2009CML14IgA-κMPIFN-α, imatinibChr, PCR, FISHP210Galanopoulos et al. [14]
1357/F2009CML65IgA-κTD, VADImatinibChr, PCRP210Michael et al. [15]
1472/F2010CML3IgG-κNo treatmentImatinibChr, PCRP210Ide et al. [16]
1571/F2012MM and CMLSimultaneousIgG-κMP, Bd, LdImatinibChrOffiah et al. [17]
1664/F2013MM and CMLSimultaneousIgA-κBDImatinibChrRomanenko et al. [18]
1762/F2013MM17IgG-κRT, VCD, VCDD, VRDDasatinibChr, PCRP210Ragupathi et al. [19]
1877/M2014MM and CMLSimultaneousIgG-κRT, BDNo treatmentChr, PCRP210Maerki et al. [20]
1960/M2014MM48IgG-κRT, LdHU, dasatinibChr, FISHAlsidawi et al. [21]
2063/F2012CML120IgG-κBD, LdImatinibChr, PCRP210Pessach et al. [22]
2168/M2012MM54IgG-λVADImatinibChr, PCRP210Pessach et al. [22]
2276/M2015CML38IgA-λNo treatmentImatinibChr, PCRAhn et al. [23]
2351/F2016MMUnknownIgGBDImatinibChr, PCRWolleschak and Heidel [24]
2488/M2016MM and CMLSimultaneousIgD-κVRDImatinibChrAli et al. [25]
2576/M2018MM28IgG-κLdDasatinib, bosutinibChr, PCR, FISHP190Our case

BJP, Bence Jones protein; MP, melphalan, prednisolone; RT, radiation therapy; HU, hydroxyurea; LOAD-IN, melphalan, ranimustine, vincristine, IFN-α; PSL, prednisolone; VCD, bortezomib, cyclophosphamide, dexamethasone; VCDD, VCD plus doxorubicin; VRD, bortezomib, lenalidomide, dexamethasone; Ld, lenalidomide, dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; BD, bortezomib, dexamethasone; CBD, BD plus cyclophosphamide; Rd, lenalidomide, dexamethasone; TD, thalidomide, dexamethasone; Chr, chromosome; PCR, polymerase chain reaction; FISH, fluorescence in situ hybridization.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.